Post by William Justice

🔹 CDMO Performance Management 🔹 Managing a CDMO isn’t enough anymore. High-performing virtual manufacturers manage the entire network. The traditional supplier scorecard is no longer sufficient. Today’s generic pharmaceutical environment demands real-time visibility across CMOs, API suppliers, 3PLs, transportation providers, and trading partners. A single weak link can quickly impact service levels, working capital, and ultimately patient access. Leading organizations are moving beyond measuring supplier performance to managing network performance. That means asking questions such as: ✔️ Which CDMOs are consistently meeting OTIF commitments? ✔️ Where are release-to-ship delays occurring? ✔️ Which lanes create the greatest freight risk or variability? ✔️ How quickly can alternate manufacturing capacity be activated? ✔️ Are serialization and EPCIS data flowing accurately across every trading partner? ✔️ Which suppliers represent the highest continuity-of-supply risk? At the same time, FDA continues encouraging supply chain partners to strengthen electronic interoperability under the Drug Supply Chain Security Act (DSCSA) while providing targeted exemptions to avoid unnecessary disruptions during implementation. The direction is clear: resilient, connected supply chains are becoming the operational standard. (U.S. Food and Drug Administration) For virtual manufacturers, competitive advantage increasingly comes from operating as one integrated enterprise, even when production is distributed across dozens of external partners. The companies that excel over the next decade will combine: • Enterprise risk management • Standardized CDMO governance • Predictive supply planning • Integrated quality and regulatory oversight • End-to-end logistics visibility • Digital performance dashboards with actionable KPIs Technology enables visibility—but governance turns visibility into better decisions. Discussion for industry leaders: If you could improve just one capability across your external manufacturing network, what would it be? 🔹 End-to-end visibility 🔹 CDMO performance management 🔹 3PL and transportation execution 🔹 Supply risk prediction 🔹 Serialization and data interoperability I’d enjoy hearing which capability you believe will create the greatest competitive advantage over the next five years. #GenericPharma #VirtualManufacturing #CDMO #SupplyChain #3PL #DSCSA #Serialization #OperationsExcellence #PharmaceuticalLeadership #DigitalTransformation